Concept And Indian Scenario
- Newborn screening (NBS) is a secondary prevention strategy that identifies treatable endocrine, metabolic, and genetic disorders presymptomatically before irreversible brain damage or death occurs.
- India has approximately 25 to 26 million births annually, representing the largest newborn cohort globally.
- Consanguinity in select regions, high birth prevalence of inborn errors of metabolism, and delayed diagnosis make screening a high clinical priority.
- A comprehensive newborn screen incorporates three pillars: dried blood spot metabolic screening, critical congenital heart disease pulse oximetry, and universal hearing screening.
Dried Blood Spot (DBS) Screening
- Timing: Blood is collected between 48 and 72 hours of life (minimum $\ge 24\text{ hours}$ after initiating milk feeds).
- Sampling before 24 hours causes false-positive TSH elevations due to the physiological neonatal TSH surge and false-negative amino acid/acylcarnitine results due to insufficient protein substrate intake.
- Method: Puncture the medial or lateral plantar border of the heel using an automated spring-loaded lancet. Avoid the posterior calcaneus to prevent osteomyelitis.
- Blood is applied to Whatman 903 or Ahlstrom 226 filter paper cards and air-dried horizontally for 3 to 4 hours at room temperature.
Core Essential Panel For India
The Indian Academy of Pediatrics (IAP) and ICMR recommend a priority minimum panel for universal implementation:
| Disorder | Primary Marker | Screening Cutoff | Clinical Consequence If Missed |
|---|---|---|---|
| Congenital Hypothyroidism (CH) | Thyroid Stimulating Hormone (TSH) | Blood spot TSH >15 to 20 $\mu\text{IU/mL}$ | Severe irreversible intellectual disability (cretinism); incidence in India is high ($\approx 1:1,000\text{ to }1:1,500$). |
| Congenital Adrenal Hyperplasia (CAH) | 17-$\alpha$-hydroxyprogesterone (17-OHP) | Stratified by gestational age and birth weight | Fatal salt-wasting shock at day 7 to 14 of life; incorrect gender assignment in virilized females. |
| G6PD Deficiency | G6PD enzyme activity (fluorometric assay) | <2.0 to 2.5 U/g Hb | Severe neonatal hyperbilirubinemia, kernicterus, acute drug- or infection-induced hemolysis. |
Expanded Screening By Tandem Mass Spectrometry (MS/MS)
- Tandem Mass Spectrometry (MS/MS) analyzes both amino acids and acylcarnitines simultaneously from a single 3-mm dried blood spot punch in under 2 minutes.
- It can identify over 40 to 50 inborn errors of metabolism:
- Amino Acidopathies: Phenylketonuria (elevated phenylalanine), Maple Syrup Urine Disease (elevated leucine, isoleucine, valine), Homocystinuria (elevated methionine).
- Organic Acidemias: Methylmalonic acidemia (elevated C3 carnitine), Propionic acidemia, Isovaleric acidemia (elevated C5 carnitine), Glutaric aciduria type 1.
- Fatty Acid Oxidation Defects: Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency (elevated C8 carnitine), VLCAD, LCHAD (prevents fasting hypoketotic hypoglycemia and sudden unexpected infant death).
Point-Of-Care Delivery Point Screening
Critical Congenital Heart Disease (CCHD) Screening
- Performed at $\ge 24\text{ hours of life}$ using motion-tolerant pulse oximeters.
- Probes are attached to the right hand (pre-ductal) and either foot (post-ductal).
- Pass: $SpO_2 \ge 95\%$ in both limbs and difference $\le 3\%$.
- Fail: $SpO_2 < 90\%$ in either limb $\rightarrow$ Urgent echocardiography.
- Equivocal: $SpO_2\ 90\text{–}94\%$ or $>3\%$ difference $\rightarrow$ Repeat in 1 hour; if fail on 3 measurements, perform echocardiography.
Universal Hearing Screening (JCIH 1-3-6 Guidelines)
- Screening completed by 1 month of age, confirmatory diagnostic testing by 3 months, and early intervention (hearing aids/cochlear implants) initiated by 6 months.
- Two-Stage Modality:
- Step 1: Automated Otoacoustic Emissions (AOAE) assesses cochlear outer hair cell function.
- Step 2: Automated Auditory Brainstem Response (AABR) is mandatory for all NICU admissions (>5 days), hyperbilirubinemia requiring exchange transfusion, asphyxia, or AOAE failure. AABR detects Auditory Neuropathy Spectrum Disorder (ANSD) which AOAE misses.
National Programs And State Models (RBSK)
- Rashtriya Bal Swasthya Karyakram (RBSK):
- Flagship national child health screening program under the National Health Mission (NHM) covering children from 0 to 18 years for the 4Ds:
- Defects at birth (Neural tube defects, cleft lip/palate, club foot, congenital cataract, congenital heart disease).
- Deficiencies (Anemia, Vitamin A and D deficiencies, severe acute malnutrition).
- Diseases (Skin conditions, otitis media, rheumatic heart disease).
- Developmental delays and disabilities (Vision, hearing, motor impairment, autism).
- Cases identified are linked to District Early Intervention Centres (DEIC) for free medical, surgical, and therapeutic management.
- Flagship national child health screening program under the National Health Mission (NHM) covering children from 0 to 18 years for the 4Ds:
- State Implementation Pioneers:
- Goa: First Indian state to implement universal newborn metabolic screening using TMS across all public and private births since 2008.
- Kerala ("NeMo" Project): State-wide screening covering congenital hypothyroidism, CAH, G6PD, and metabolic disorders integrated into electronic tracking.
- Chandigarh & Delhi: Systematic hospital-based universal screening models with established diagnostic recall networks.
Molecular And Genomic Frontiers
- PCR testing on dried blood spots identifies T-cell receptor excision circles (TREC) to detect Severe Combined Immunodeficiency (SCID).
- PCR screening for homozygous SMN1 exon 7 deletion enables presymptomatic diagnosis and gene therapy for Spinal Muscular Atrophy.
- Genomic newborn screening using targeted next-generation sequencing is being piloted for dozens of monogenic conditions.